Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer

Affiliation auteurs!!!! Error affiliation !!!!
TitreResults of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer
Type de publicationJournal Article
Year of Publication2021
AuteursDuffaud F., Chabaud S., Chevreau C.M, Italiano A., Perrin C., Isambert N., Piperno-Neumann S., Saada-Bouzid E., Bertucci F., Cupissol D., Kalbacher E., Narciso B., Schiffler C., N. Carvalho deSousa, Monard L., Bouvier C., Vidal V., Blay J-Y., Mir O.
JournalANNALS OF ONCOLOGY
Volume32
PaginationS1335
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2021.08.2138